Patterson BJ, Buck PO, Curran D, van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021 May 26;5(3):596-604. doi: 10.1016/j.mayocpiqo.2021.03.006
Earnshaw SR, Wilson M, Joshi AV. The effect of recombinant activated factor VII in the treatment of intracerebral hemorrhage on health plan budgets. Managed Care Interface. 2007 Jan 1;19(11):39-45.
Earnshaw SR, Wilson MR, Joshi AV. Health plan budget impact analysis of recombinant activated factor VII (rFVIIa) in the treatment of intracerebral hemorrhage. Managed Care Interface. 2006;19(11):39-45.
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.